Paricalcitol – Nebenschilddrüsenantagonist mit kardiorenalen Effekten

Ein Gespräch mit Dr. Sven Baumann, Medical Manager Renal Care, Abbott GmbH & Co. KG, Ludwigshafen.

Dr. Sven Baumann

• Literatur

• 1 Martin KJ et al. J Am Soc Nephrol 1998; 9: 1427-1432
• 2 Llach F, Yudd M. Am J Kidney Dis 2001; 38 (Suppl. 05) 45-50
• 3 Teng M et al. N Eng J Med 2003; 349: 446-456
• 4 Kalantar-Zadeh K et al. Kidney Int 2006; 70: 771-780
• 5 Fishbane S et al. Randomized controlled trial to evaluate survival benefits of Paricalcitol relative to Calcitriol in hemodialysis patients: Termination secondary to inability to enroll based on perceived ethical concerns. Abstract M642 WCN congress 2009
• 6 Agarwal R et al. Kidney Int 2005; 68: 2823-2828
• 7 Bodyak N et al. Proc Natl Acad Sci USA 2007; 104: 16810-16815
• 8 Cardús A et al. J Bone Miner Res 2007; 22: 860-866
• 9 Mizobuchi M et al. Kidney Int 2007; 72: 709-715
• 10 Alborzi P et al. Hypertension 2008; 52: 249-255
• 11 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Kidney Int Suppl 2009; 113: 1-130